Jonathan Louw, MB.ChB, MBA, is the Group CEO of Honoris United Universities, the largest Pan-African Tertiary Education Institution with over 70,000 students. He is also a member of the South African National Dept. of Health's Pricing Committee that regulates the Country's healthcare pricing.
Prior to this he was the CEO of the South African National Blood Service (SANBS) from 2017-2020,catering to the collection, processing, testing and distribution of blood and related products across South Africa.
From 2014-2017 he was also a Managing Director at one of the largest private equity firms in the Middle East, raising and deploying $1bn in hospitals and diagnostics in global markets. He worked across the business assisting Partner Companies with improving operational, financial, ESG and workforce performance. Prior to this, Dr. Louw worked at Adcock Ingram Holdings Limited (JSE:AIP) and was the CEO from Jan 2003 until May 2014. Adcock Ingram is a South African Healthcare company with operations across Sub-Saharan Africa and India, in branded generics, multinational patented products, hospital products and consumer products with leading market shares in all categories. Dr. Louw led the IPO of Adcock Ingram when it separated from the JSE-Listed TigerBrands in 2008 and during his tenure the business adopted an aggressive growth strategy, re-investing in manufacturing and R&D to achieve FDA and PIC/s accreditation in both. The distribution capability was improved through automation and successful integration of Oracle, and numerous acquisitions and license agreements were consummated to diversify the business internationally and enter new fast-growing categories. Dr Louw first joined the pharmaceutical industry through AstraZeneca in 2000. He worked in the Department of Anesthesia at St. Mary's Hospital in London, having trained as an undergraduate at the University of Cape Town in the faculty of Medicine. He has also served as the President of the Pharmaceutical Industry Association of South Africa in 2009/10, representing the interest of local and multi-national pharmaceutical companies, and is a Board member of Generation Ubuntu (NYC) looking after Orphans afflicted with HIV/AIDS in South Africa.
